TY - JOUR
T1 - β2-Adrenergic receptor regulate Toll-like receptor 4-induced late-phase NF-κB activation
AU - Kizaki, Takako
AU - Shirato, Ken
AU - Sakurai, Takuya
AU - Ogasawara, Jun etsu
AU - Oh-ishi, Shuji
AU - Matsuoka, Takeshi
AU - Izawa, Tetsuya
AU - Imaizumi, Kazuhiko
AU - Haga, Shukoh
AU - Ohno, Hideki
PY - 2009/3
Y1 - 2009/3
N2 - Stimulation of Toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) triggers myeloid differentiation factor 88 (MyD88)-dependent early-phase NF-κB activation and Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent late-phase NF-κB activation. In a previous study, we have shown that β2-adrenergic receptor (β2AR) functions as a negative regulator of NF-κB activation through β-arrestin 2 in the macrophage cell line RAW264 and that down-regulation of β2AR expression in response to LPS is essential for NF-κB activation and expression of its target gene, inducible nitric oxide synthase (NOS II). Here, we demonstrate that β2AR plays an important role in TRIF-dependent late-phase NF-κB activation. LPS-stimulated down-regulation was induced in MyD88-knockdown cells, but not in TRIF-knockdown cells, suggesting that β2AR expression was down-regulated by the TRIF-dependent pathway. On the other hand, depletion of β2AR or β-arrestin 2 expression by siRNA decreased cytoplasmic IκBα and abrogated late-phase IκBα degradation and NF-κB activation in response to LPS. Inducible nitric oxide synthase (NOS II) expression was increased continuously during 24 h of LPS stimulation in control cells, but decreased in β2AR or β-arrestin 2-knockdown cells after 6 h of LPS stimulation. These findings suggest that β2AR functions not only as a negative regulator of NF-κB activation, but also as a stabilizing factor of the NF-κB/IκBα complex through cytoplasmic β-arrestin 2, and that TRIF-dependent down-regulation of β2AR expression increases the level of cytoplasmic NF-κB/IκBα complex free from β-arrestin 2, leading to continuous late-phase NF-κB activation.
AB - Stimulation of Toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) triggers myeloid differentiation factor 88 (MyD88)-dependent early-phase NF-κB activation and Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent late-phase NF-κB activation. In a previous study, we have shown that β2-adrenergic receptor (β2AR) functions as a negative regulator of NF-κB activation through β-arrestin 2 in the macrophage cell line RAW264 and that down-regulation of β2AR expression in response to LPS is essential for NF-κB activation and expression of its target gene, inducible nitric oxide synthase (NOS II). Here, we demonstrate that β2AR plays an important role in TRIF-dependent late-phase NF-κB activation. LPS-stimulated down-regulation was induced in MyD88-knockdown cells, but not in TRIF-knockdown cells, suggesting that β2AR expression was down-regulated by the TRIF-dependent pathway. On the other hand, depletion of β2AR or β-arrestin 2 expression by siRNA decreased cytoplasmic IκBα and abrogated late-phase IκBα degradation and NF-κB activation in response to LPS. Inducible nitric oxide synthase (NOS II) expression was increased continuously during 24 h of LPS stimulation in control cells, but decreased in β2AR or β-arrestin 2-knockdown cells after 6 h of LPS stimulation. These findings suggest that β2AR functions not only as a negative regulator of NF-κB activation, but also as a stabilizing factor of the NF-κB/IκBα complex through cytoplasmic β-arrestin 2, and that TRIF-dependent down-regulation of β2AR expression increases the level of cytoplasmic NF-κB/IκBα complex free from β-arrestin 2, leading to continuous late-phase NF-κB activation.
KW - β-Arrestin 2
KW - β-Adrenergic receptor
KW - IκBα
KW - Inducible nitric oxide synthase
KW - Lipopolysaccharide
KW - Macrophages
KW - NF-κB
KW - Toll-like receptor-4
UR - http://www.scopus.com/inward/record.url?scp=60949101623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60949101623&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2008.11.005
DO - 10.1016/j.molimm.2008.11.005
M3 - Article
C2 - 19167076
AN - SCOPUS:60949101623
SN - 0161-5890
VL - 46
SP - 1195
EP - 1203
JO - Molecular Immunology
JF - Molecular Immunology
IS - 6
ER -